UTokyo IPC has invested $5 million in STORM Therapeutics, a UK-based biotech firm developing RNA-modifying enzyme-targeted therapeutics, as part of a broader $30 million co-investment initiative.

Information on the Target

STORM Therapeutics Ltd, based in Cambridge, UK and led by CEO Jerry McMahon, PhD, is an innovative biotech company focused on the research and development of small molecule therapeutics targeting RNA-modifying enzymes (RMEs). These enzymes play a crucial role in post-transcriptional modifications of RNA, which have been implicated in various diseases, including cancer. STORM is advancing clinical-stage drug candidates and has developed a robust pipeline, with its lead program, STC-15, being a first-in-class METTL3 inhibitor that commenced Phase 1 clinical trials for solid tumors in 2022. Notably, Professor Tsutomu Suzuki from the University of Tokyo serves on STORM's Scientific Advisory Board, contributing leading research in RNA modifications.

Industry Overview in the Target’s Specific Country

The biotechnology sector in the UK is recognized as one of the most advanced globally, driven by a combination of strong academic research, innovative startups, and significant investments. The country boasts a rich history of excellence in life sciences, with institutions like the University of Cambridge fostering groundbreaking research that translates into commercial opportunities. In recent years, the UK biotech industry has experienced rapid growth, significantly contributing to the economy and enhancing global health through innovative medical solutions.

Exploring the specific area of RNA-based therapeutics, there is increasing recognition of the potential for RNA modifications in developing effective treatments for complex diseases such as cancer and g